Microvascular Invasion Is a Better Predictor of Tumor Recurrence and Overall Survival Following Surgical Resection for Hepatocellular Carcinoma Compared to the Milan Criteria

米兰标准 医学 肝细胞癌 肝移植 内科学 比例危险模型 外科 肿瘤科 移植
作者
Kheng-Choon Lim,Pierce K. H. Chow,John Carson Allen,Ghim-Song Chia,Miao Shan Lim,Peng Chung Cheow,Alexander Chung,London Lucien Ooi,Say‐Beng Tan
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
卷期号:254 (1): 108-113 被引量:462
标识
DOI:10.1097/sla.0b013e31821ad884
摘要

To compare microvascular invasion (McVI) with parameters defined by the Milan criteria in predicting tumor recurrence and overall survival (OS) in patients with surgical resection (SR) for hepatocellular carcinoma (HCC).Although the Milan criteria is discriminatory for selecting patients with good outcomes in liver transplantation and SR for HCC, it neither adequately predict tumor recurrence nor explain differences in survival for patients with good liver function. McVI is a strong indicator of intrahepatic metastasis in HCC, but its relative significance for predicting clinical outcomes compared to the Milan criteria is unclear.Patients undergoing SR with curative intent from January 2000 to March 2009 at the Singapore General Hospital were followed up for long-term outcomes till January 1, 2010. They were stratified first by the Milan criteria and then by the presence of McVI and compared relative to OS.Altogether, 454 of the 515 patients received curative SR. There were stratified into 4 groups (Milan+, McVI-), (Milan+, McVI+), (Milan-, McVI-), and (Milan-, McVI+). All pair-wise comparisons between groups relative to OS were significant except (Milan+, McVI-) (OS, 90%, 73%, and 60% at 1, 3, and 5 years) with (Milan-, McVI-) (OS, 86%, 71%, and 61% at 1, 3, 5 years) and (Milan+, McVI+) with (Milan-, McVI+). Multivariate Cox regression analysis showed that McVI was predictive of OS, after which Milan status did not add additional discriminative information.McVI is a better predictor of tumor recurrence and OS than the Milan criteria after SR for HCC. Assessment of McVI should aid in patient selection for adjuvant treatments to improve outcomes after SR.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
luxx完成签到,获得积分10
1秒前
1秒前
2秒前
量子星尘发布了新的文献求助10
2秒前
四季完成签到,获得积分10
3秒前
五十完成签到,获得积分10
3秒前
coco完成签到,获得积分10
3秒前
3秒前
Owen应助听风采纳,获得10
3秒前
3秒前
shining完成签到,获得积分10
4秒前
suyuan发布了新的文献求助10
4秒前
有人管发布了新的文献求助30
5秒前
6秒前
Peng发布了新的文献求助10
6秒前
7秒前
好结局完成签到 ,获得积分10
7秒前
四季发布了新的文献求助10
8秒前
Jasper应助虚幻的珩采纳,获得10
9秒前
Akim应助大胆龙猫采纳,获得10
9秒前
游一完成签到,获得积分10
10秒前
舒心的大有完成签到,获得积分10
10秒前
小管家完成签到,获得积分10
10秒前
10秒前
哩哩完成签到 ,获得积分10
10秒前
11秒前
量子星尘发布了新的文献求助10
11秒前
12秒前
12秒前
13秒前
13秒前
AJ发布了新的文献求助10
14秒前
14秒前
emma发布了新的文献求助50
14秒前
闲云野鹤完成签到,获得积分10
15秒前
彭于晏应助shell采纳,获得30
15秒前
英姑应助付研琪采纳,获得10
15秒前
烤麸完成签到,获得积分10
15秒前
小辰发布了新的文献求助10
16秒前
高分求助中
2025-2031全球及中国金刚石触媒粉行业研究及十五五规划分析报告 15000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1000
Russian Foreign Policy: Change and Continuity 800
Real World Research, 5th Edition 800
Qualitative Data Analysis with NVivo By Jenine Beekhuyzen, Pat Bazeley · 2024 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5700730
求助须知:如何正确求助?哪些是违规求助? 5140373
关于积分的说明 15231782
捐赠科研通 4855900
什么是DOI,文献DOI怎么找? 2605520
邀请新用户注册赠送积分活动 1556868
关于科研通互助平台的介绍 1514960